Ao Hui, Feng Wuwen, Peng Cheng
College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.
Innovative Institute of Chinese Medicine and Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.
Evid Based Complement Alternat Med. 2018 Sep 25;2018:8259280. doi: 10.1155/2018/8259280. eCollection 2018.
Hydroxysafflor yellow A (HSYA) is one of the major bioactive and water-soluble compounds isolated from Carthami Flos, the flower of safflower ( L.). As a natural pigment with favorable medical use, HSYA has gained extensive attention due to broad and effective pharmacological activities since first isolation in 1993. In clinic, the safflor yellow injection which mainly contains about 80% HSYA was approved by the China State Food and Drug Administration and used to treat cardiac diseases such as angina pectoris. In basic pharmacology, HSYA has been proved to exhibit a broad spectrum of biological effects that include, but not limited to, cardiovascular effect, neuroprotection, liver and lung protection, antitumor activity, metabolism regulation, and endothelium cell protection. Although a great number of studies have been carried out to prove the pharmacological effects and corresponding mechanisms of HYSA, a systemic review of HYSA has not yet been seen. Here, we provide a comprehensive summarization of the pharmacological effects of HYSA. Together with special attention to mechanisms of actions, this review can serve as the basis for further researches and developments of this medicinal compound.
羟基红花黄色素A(HSYA)是从红花(Carthamus tinctorius L.)的花中分离得到的主要生物活性水溶性化合物之一。作为一种具有良好药用价值的天然色素,自1993年首次分离以来,HSYA因其广泛而有效的药理活性受到了广泛关注。临床上,主要含有约80% HSYA的红花黄色素注射液已获中国国家食品药品监督管理总局批准,用于治疗心绞痛等心脏病。在基础药理学方面,已证明HSYA具有广泛的生物学效应,包括但不限于心血管效应、神经保护、肝脏和肺保护、抗肿瘤活性、代谢调节和内皮细胞保护。尽管已经进行了大量研究来证明HSYA的药理作用及相应机制,但尚未见对HSYA的系统综述。在此,我们对HSYA的药理作用进行了全面总结。同时特别关注其作用机制,本综述可为该药用化合物的进一步研究和开发提供依据。